Alon Natanson

We're thrilled to announce a new strategic partnership with Israel-based Eldan Neopharm Group for distribution of the Resipher platform! Established in 1960, Eldan is one of the largest and most influential companies in the Israeli healthcare sector - specializing in scientific instruments, equipment, and medical devices. This agreement allows us to expand our reach internationally through a highly reputable partner, bringing #Resipher technology to a wider audience and continuing to move research forward. You can find Eldan at this week's #Isranalytica show in Tel Aviv, kicking off Wednesday - stop by their booth to learn more or visit their website here >>> https://lnkd.in/eQpCECte

7

New partnership aimed at advancing Israeli pharma giant's anti-IL-15 drug for autoimmune diseases; CEO Richard Francis to detail growth strategy and pipeline progress at J.P. Morgan Healthcare Conference on Jan. 13 *** Teva Pharmaceuticals and Royalty Pharma announced on Sunday a funding agreement of up to $500 million to accelerate development of TEV-’408, Teva’s experimental treatment targeting autoimmune diseases including vitiligo. Under the agreement, Royalty Pharma will initially provide $75 million to support a Phase 2b trial of TEV-’408 for vitiligo, expected to begin in 2026. Pending trial results, Royalty Pharma may invest an additional $425 million to co-fund a Phase 3 program. If approved, Teva will pay Royalty Pharma milestone payments and royalties on global sales. TEV-’408 is a monoclonal antibody designed to block interleukin-15 (IL-15), a cytokine involved in multiple immune-mediated conditions. The treatment is currently in Phase 1b trials for vitiligo and Phase 2a trials for celiac disease. It received Fast Track designation from the U.S. Food and Drug Administration in May 2025. Preliminary trial data support IL-15 as a promising therapeutic target for autoimmune disorders. Vitiligo, a chronic skin condition causing loss of pigmentation, affects 0.5% to 2% of the global population and currently has only one approved topical therapy with limited application. Full article: https://bit.ly/3NoMB5T Teva Pharmaceuticals Royalty Pharma Sharon Shalmon Esman #YnetGlobal #AutoimmuneDisease #Drugs #medicine #teva #RoyaltyPharma

16

Signing ceremony for new Israel National Biotech Innovation Center The Gray Faculty of Medical and Health Sciences Tel Aviv University is extremely pleased to be part of the new Israel National Biotech Innovation Center (INBI), a transformational hub made up of Israel's leading research institutions and medical centers. Together, they will work in world-class biomedical research and accelerate the development of breakthrough therapeutics. The goal of the INBI is to bridge the translational gap and create a pathway from groundbreaking science to new medicines. We are excited to join our hospital and HMO partners, the Sheba Medical Center, Tel Hashomer, Beilinson Hospital - Rabin Medical Center, Tel Aviv Sourasky Medical Center (Ichilov) and Maccabi Healthcare Services and Clalit Health Services. Bar-Ilan University, Ben-Gurion University of the Negev, Hadassah Medical Center, The Hebrew University of Jerusalem, Rambam Health Care Campus, Shaare Zedek Medical Center, The Technion – Israel Institute of Technology, The University of Haifa and the Weizmann Institute of Science are also partnering institutions and medical centers. A special thank you to Sam Moed and Tom Rice for all their hard work to bring us to this stage. The INBI will be led by Anat Cohen-Dayag, and will focus on building the organization, advancing the project selection process, securing the resources required for implementation, and working toward the launch of INBI’s first project cohort in 2027. Photos from the signing ceremony: from left to right, Noam Shomron, Sam Moed, Karen B. Avraham, Ronen Kreizman Anat Cohen-Dayag, Ronit Satchi-Fainaro Photo credit: Yossi Zwecker

89